Efficacy and safety of Xinmai'an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis.

Background: Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the treatment of premature ventricular contractions due to CHD mainly focuses on catheter ablation, beta-blockers and antiarrhythmics. Both require ongoing monitoring because relapses may lead to redevelopment of cardiomyopathy, and there are varying degrees of indications and side effects. Several clinical studies have shown that Xinmai'an can effectively control the occurrence of premature ventricular contractions and reduce the risk of recurrence. However, there is currently no systematic review evaluating its effectiveness. Therefore, the purpose of this study is to provide strong evidence-based medical evidence for Xinmai'an tablet in the treatment of premature ventricular contractions due to CHD.

Methods: We will search the main Chinese and English databases from inception to June 5, 2022. And identified as the randomized controlled trials. In addition, a reference list of studies meeting the inclusion criteria will be retrieved. Two researchers will conduct literature screening and quality evaluation. And we will conduct bias risk assessment and sensitivity analysis. The analysis software uses RevMan 5.3.

Results: Mainly by observing the number of ventricular premature beat attacks (24-hour holter monitoring electrocardiogram), electrocardiogram efficacy (ST segment and T wave changes) and echocardiogram assesses the structure and function of the left and right ventricular, left ventricular ejection fraction, etc. To evaluate the clinical effect of Xinmai'an on premature ventricular contractions due to CHD.

Conclusion: The results of this study will provide a basis for the selection of treatment options for premature ventricular contractions due to CHD.